🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-525517-31-00
Terminated Phase I

A PHASE 1, OPEN-LABEL, SINGLE-DOSE MASS BALANCE AND METABOLITE PROFILING STUDY OF 14C-LABELED IZICOPAN (INF904) IN HEALTHY MALE PARTICIPANTS

2026-525517-31-00 · tracked via the Priya Life Science EU tracker
Sponsor
InflaRx GmbH
Sponsor type
Pharmaceutical company
Therapeutic area
Not possible to specify
Decision date
01/05/2026
Enrollment target
8
Sites
Netherlands

Condition studied

Not applicable, healthy volunteers

Eligibility

Age group
18-64 years
Sex
Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525517-31-00 on CTIS ↗ ← All trials in the EU